Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Melanoma 2Colitis 2Lung Neoplasms 1

Interventions

fludarabine 3aldesleukin 3Cyclophosphamide 3vedolizumab 2atezolizumab 2Riluzole 2LDP-02 2Infliximab 2Immunoglobulin G 2Fecal Microbiota Transplantation 2Disulfides 2CT-P13 2prednylidene 1pembrolizumab 1motexafin gadolinium 1deltacortene 1Tinzaparin 1Therapeutics 1Taste 1Standard of Care 1Radiotherapy 1Prednisone 1Practice Guidelines as Topic 1Loperamide 1Interleukin-2 1Immunotherapy 1Geriatric Assessment 1Fatty Acids, Omega-3 1Exercise 1Endoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urogenital Neoplasms × vedolizumab × Thoracic × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡